Why the study?
Hypertension drives cardiac hypertrophy and heart failure, with Mef2 identified as a primary effector, prompting a survey of literature to illuminate points of interest for understanding and potentially treating heart failure.
This review highlights the role of Mef2 in hypertension-induced cardiac hypertrophy, suggesting it as a potential therapeutic target for heart failure.
Mef2 activation in pressure-overload models does not yet inform practice; leaves open targeted interventional validation in hypertension.
Hypertension is a globally prevalent pathological condition and an underlying risk factor for the development of cardiac hypertrophy leading to heart failure. Myocyte enhancer factor 2 (Mef2) has been identified as one of the primary effectors of morphological changes in the hypertensive heart, as part of a complex network of molecular signaling controlling cardiac gene expression. Experimental chronic pressure-overload models that mimic hypertension in the mammalian heart lead to the activation of various pathological mechanisms that result in structural changes leading to debilitating cardiac hypertrophy and ultimately heart failure. The purpose here is to survey the literature implicating Mef2 in hypertension induced cardiac hypertrophy, towards illuminating points of interest for understanding and potentially treating heart failure.
No takes yet. Share an insight, caveat, or question.
Cornwell et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: